• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

弥漫性脑膜瘤中组织病理学特征和 H3K27me3 免疫标记丢失的预后价值:一项多中心回顾性研究。

Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study.

机构信息

INSERM U1256, Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy.

Department of Pathology, CHRU, Nancy, France.

出版信息

J Neuropathol Exp Neurol. 2020 Jul 1;79(7):754-762. doi: 10.1093/jnen/nlaa038.

DOI:10.1093/jnen/nlaa038
PMID:32447376
Abstract

The diagnosis of anaplastic meningioma (AM) (WHO grade III) is based on the presence of a high mitotic index (MI) and/or overt anaplasia. Only few data exist about the reproducibility and prognostic value of overt anaplasia. Additionally, the prognostic value of H3K27me3 loss in AM has not yet been demonstrated. Our objectives were to evaluate the reproducibility and prognostic value of WHO criteria and H3K27me3 loss in a multicenter series of 66 AM. Interobserver reproducibility was good for the determination of WHO grade (Kappa = 0.671) and MI (intraclass correlation coefficient [ICC] = 0.649), and fair for assessment of overt anaplasia (Kappa = 0.366). Patients with meningiomas showing high MI had significantly shorter overall survival (OS) than patients with meningiomas showing overt anaplasia without high MI (p = 0.009). OS was significantly lower in case of overt anaplasia with low MI (<20/1.6 mm2) than in atypical meningiomas (p = 0.008). H3K27me3 loss was present in 10/47 (21%) of AM and independently associated with shorter OS (p = 0.036; Cox multivariate analysis), with a good reproducibility (Kappa = 0.643). In conclusion, the presence of overt anaplasia could give additional prognostic information in tumors lacking high MI. Finally, loss of H3K27me3 is an easy-to-use and reproducible marker of poorer prognosis.

摘要

间变性脑膜瘤(AM)(WHO 分级 III)的诊断基于存在高有丝分裂指数(MI)和/或明显间变。关于明显间变的可重复性和预后价值仅有很少的数据。此外,H3K27me3 缺失在 AM 中的预后价值尚未得到证实。我们的目的是在 66 例 AM 的多中心系列中评估 WHO 标准和 H3K27me3 缺失的可重复性和预后价值。确定 WHO 分级(Kappa = 0.671)和 MI(组内相关系数 [ICC] = 0.649)的观察者间可重复性良好,评估明显间变的可重复性为一般(Kappa = 0.366)。具有高 MI 的脑膜瘤患者的总生存期(OS)明显短于具有高 MI 但无明显间变的脑膜瘤患者(p = 0.009)。具有低 MI(<20/1.6 mm2)的明显间变的 OS 明显低于非典型脑膜瘤(p = 0.008)。在 47 例 AM 中有 10 例(21%)存在 H3K27me3 缺失,与较短的 OS 独立相关(p = 0.036;Cox 多变量分析),具有良好的可重复性(Kappa = 0.643)。总之,在缺乏高 MI 的肿瘤中,明显间变的存在可能提供额外的预后信息。最后,H3K27me3 的缺失是预后较差的一种易于使用和可重复的标志物。

相似文献

1
Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study.弥漫性脑膜瘤中组织病理学特征和 H3K27me3 免疫标记丢失的预后价值:一项多中心回顾性研究。
J Neuropathol Exp Neurol. 2020 Jul 1;79(7):754-762. doi: 10.1093/jnen/nlaa038.
2
De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.原发性和继发性间变性脑膜瘤:临床和组织分子预后因素研究。
Neuro Oncol. 2018 Jul 5;20(8):1113-1121. doi: 10.1093/neuonc/nox231.
3
Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.组蛋白 H3K27me3 的缺失鉴定出一组具有更高复发风险的脑膜瘤。
Acta Neuropathol. 2018 Jun;135(6):955-963. doi: 10.1007/s00401-018-1844-9. Epub 2018 Apr 7.
4
The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma.大量 H3K27me3 的丢失可对 2 级而非 3 级脑膜瘤进行风险分层。
Hum Pathol. 2021 Sep;115:96-103. doi: 10.1016/j.humpath.2021.06.005. Epub 2021 Jun 26.
5
Infarction with associated pseudosarcomatous changes mimics anaplasia in otherwise grade I meningiomas.伴有假性肉瘤样改变的梗死类似于其他 I 级脑膜瘤中的间变。
Mod Pathol. 2020 Jul;33(7):1298-1306. doi: 10.1038/s41379-020-0491-6. Epub 2020 Feb 11.
6
"Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications.脑膜瘤中的“恶性”:116例患者的临床病理研究及其分级意义
Cancer. 1999 May 1;85(9):2046-56. doi: 10.1002/(sici)1097-0142(19990501)85:9<2046::aid-cncr23>3.0.co;2-m.
7
Angiomatous meningioma: a clinicopathologic study of 38 cases.血管母细胞瘤型脑膜瘤:38例临床病理研究
Am J Surg Pathol. 2004 Mar;28(3):390-3. doi: 10.1097/00000478-200403000-00013.
8
Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.抗磷酸化组蛋白H3抗体免疫染色在脑膜瘤病例有丝分裂计数中的敏感性和实用性。
Brain Tumor Pathol. 2009;26(2):51-7. doi: 10.1007/s10014-009-0249-9. Epub 2009 Oct 27.
9
Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.Ki-67增殖指数可预测非典型或间变性脑膜瘤患者的临床预后。
Neuropathology. 2007 Apr;27(2):114-20. doi: 10.1111/j.1440-1789.2007.00750.x.
10
Pathodiagnostic parameters for meningioma grading.脑膜瘤分级的病理诊断参数。
J Clin Neurosci. 2008 Dec;15(12):1370-5. doi: 10.1016/j.jocn.2007.12.005. Epub 2008 Sep 26.

引用本文的文献

1
EZH2 overexpression is associated with aggressive behavior and promotes cell proliferation in CNS WHO grade 3 meningiomas.EZH2过表达与侵袭性行为相关,并促进中枢神经系统WHO 3级脑膜瘤的细胞增殖。
Neurooncol Adv. 2025 Jun 5;7(1):vdaf112. doi: 10.1093/noajnl/vdaf112. eCollection 2025 Jan-Dec.
2
Advancements in the application of MRI radiomics in meningioma.磁共振成像放射组学在脑膜瘤中的应用进展
Radiat Oncol. 2025 Jul 1;20(1):105. doi: 10.1186/s13014-025-02679-8.
3
Real-Time Detection of Meningiomas by Image Segmentation: A Very Deep Transfer Learning Convolutional Neural Network Approach.
通过图像分割实时检测脑膜瘤:一种基于深度迁移学习的卷积神经网络方法。
Tomography. 2025 Apr 24;11(5):50. doi: 10.3390/tomography11050050.
4
The prognostic value of H3 K27me3 in meningiomas: A review on current evidence and methodological challenges.H3 K27me3在脑膜瘤中的预后价值:当前证据及方法学挑战综述
Histol Histopathol. 2025 Jun;40(6):797-803. doi: 10.14670/HH-18-851. Epub 2024 Nov 21.
5
H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic Implications.中枢神经系统肿瘤中H3K27me3缺失:诊断、预后及治疗意义
Cancers (Basel). 2024 Oct 11;16(20):3451. doi: 10.3390/cancers16203451.
6
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.cIMPACT-NOW更新8:脑膜瘤分子风险参数的澄清及世界卫生组织分级建议
Neuro Oncol. 2025 Feb 10;27(2):319-330. doi: 10.1093/neuonc/noae170.
7
Malignant Transformation of Meningioma With Promoter Mutation: A Case Report.伴有启动子突变的脑膜瘤恶性转化:病例报告
Brain Tumor Res Treat. 2024 Jul;12(3):192-199. doi: 10.14791/btrt.2024.0023.
8
Pembrolizumab in an HIV-infected patient with glioblastoma.帕博利珠单抗治疗 HIV 感染合并胶质母细胞瘤患者。
Immunotherapy. 2024;16(12):803-811. doi: 10.1080/1750743X.2024.2362566. Epub 2024 Jun 18.
9
Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates.脑膜瘤:2021年世界卫生组织中枢神经系统肿瘤分类的分子更新及影像关联
AJNR Am J Neuroradiol. 2025 Feb 3;46(2):240-250. doi: 10.3174/ajnr.A8368.
10
Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution.脑膜瘤异质性和演变背后的空间基因组、生化和细胞机制。
Nat Genet. 2024 Jun;56(6):1121-1133. doi: 10.1038/s41588-024-01747-1. Epub 2024 May 17.